Loading company financials…
NASDAQ NMS - GLOBAL MARKET · Pharmaceuticals · CIK 0001792044
$18.65
+2.14% · delayed ~15 min
Last price from Oct 20, 2026
$22.12B market value
From Viatris Inc's FY2025 10-K, filed Feb 26, 2026 · read the filing
Viatris develops and makes medicines. It took in $14.25B last year, which makes it a large company. It spends more than it earns — losing about 25 cents on every dollar of sales.
The financial picture is led by accounting, while profitability, growth and debt remain weak.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
A published bankruptcy-risk model places it in its distress range. This is a statistical reading, not a forecast.
Altman Z-Score 0.81
These are things the company filed or that a published model flagged — not predictions, and not a reason on their own to buy or sell anything.
Financial health
Several areas of financial weakness.
From Viatris Inc's FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Operating income
$10.1M → -$2.66B
Profit
-$634.2M → -$3.51B
Operating margin
0.1% → -18.7%
Profit margin
-4.3% → -24.7%
Measured against FY2024, from the 10-K filed Feb 26, 2026
Deteriorated: turned negative
$10.1M to -$2.66BCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: $2.88B wider
-$634.2M to -$3.51BCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
How the latest move compares (quote delayed ~15 min), and what was published around it
VTRS rose 2.14% on the latest quote. The average Health Care company tracked here moved +1.65%, and the S&P 500 −1.04%. That is in line with its sector and 3.2 points above the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 4% a year for the next 10 years. Over the last 7 years it shrank by about 1% a year.
The essentials
Each answered from the filings, with the numbers behind it.
No. It lost $3.51B last year, losing about 25 cents on every dollar of sales.
No. Sales shrank 3.0% last year.
Manageable, but notable. Clearing its debt would take about 5.7 years of cash flow. For every $1 it owes, it owns $1.65 in assets. Its operating profit does not cover its interest bill — -5.65x against the interest it owes. A bankruptcy-risk model also places it in its distress range.
Core operating and valuation reference metrics
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2025 annual filing
Last year it lost $3.51B and generated $2.32B of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 26, 2026Filing for FY2025 | FY202410-K · Feb 26, 2026Filing for FY2024 | FY202310-K · Feb 26, 2026Filing for FY2023 | FY202210-K · Feb 27, 2025Filing for FY2022 | FY202110-K · Feb 28, 2022Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $14.25B | $14.69B | $15.39B | $16.22B | $17.81B | −3.0% |
| Cost of revenue | $9.29B | $9.12B | $8.99B | $9.77B | $12.31B | +1.9% |
| Gross profit | $5.01B | $5.62B | $6.44B | $6.50B | $5.58B | −10.8% |
| Gross marginGross profit ÷ revenueWhat is this? | 35.2% | 38.3% | 41.8% | 40.1% | 31.3% | −3.1 pts |
| Selling, general and administrative | $3.79B | $4.10B | $4.07B | $4.18B | $4.53B | −7.6% |
| Operating income | -$2.66B | $10.1M | $766.2M | $1.61B | -$34.0M | n/m |
| Operating marginOperating income ÷ revenueWhat is this? | -18.7% | 0.1% | 5.0% | 10.0% | -0.2% | −18.8 pts |
| Interest expense | $471.3M | $550.0M | $573.1M | $592.4M | $636.2M | −14.3% |
| Income before tax | -$3.67B | -$623.2M | $202.9M | $2.81B | -$664.4M | −488.1% |
| Net income | -$3.51B | -$634.2M | $54.7M | $2.08B | -$1.27B | −454.2% |
| Net marginNet income ÷ revenueWhat is this? | -24.7% | -4.3% | 0.4% | 12.8% | -7.1% | −20.3 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $-2.96 | $-0.5326 | $0.0456 | $1.71 | $-1.05 | −456.5% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| VTRSViatris Inc · this page | 4.0/10 | 5/9 | -3.0% |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Exercised stock options — 25,134 shares
Holds 244,811 shares after this filing.
Had shares withheld to cover taxes — 10,931 shares at $16.23 ($177.4K)
Holds 233,880 shares after this filing.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Signed a material agreement · Reported another event
Read the filingQuarterly report for Q2 FY2026
Operating margin −6.4 pts · Operating income -97.3% · Profit $114.2M wider — against Q2 FY2025
Read the filingWrite down why you are following Viatris Inc, what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 276 subsidiaries named in its 10-K, incorporated across 71 places. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from VTRS's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 26, 2026), reported under the US GAAP taxonomy. View the source filing.
4 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. All four had enough reported figures. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 9 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 4.0 | 5/9 | 10-K, filed Feb 26, 2026 |
| FY2024 | 4.0 | 5/9 | 10-K, filed Feb 27, 2025 |
| FY2023 | 5.0 | 7/9 | 10-K, filed Feb 28, 2024 |
| FY2022 | 6.0 | 7/9 | 10-K, filed Feb 27, 2023 |
| FY2021 | 6.0 | 4/9 | 10-K, filed Feb 28, 2022 |
| FY2020 | 4.0 | 4/9 | 10-K, filed Mar 1, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
5 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
0.81
In the distress zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-3.27
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Deteriorated: −18.8 pts
0.1% to -18.7%Critical
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Deteriorated: −20.3 pts
-4.3% to -24.7%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: $2.43 wider
-$0.53 to -$2.96Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +80.0%
$734.8M to $1.32BCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Deteriorated: −3.1 pts
38.3% to 35.2%Significant
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Changed: +16.2%
$326.0M to $378.8MSignificant
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
Deteriorated: -10.8%
$5.62B to $5.01BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: -11.1%
$14.04B to $12.48BNotable
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Q2 FY2026 against Q2 FY2025, from the 10-Q filed Aug 6, 2026 — read it.
Deteriorated: -97.3%
$233.0M to $6.3MCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: $114.2M wider
-$4.6M to -$118.8MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Deteriorated: $0.10 wider
-$0.00 to -$0.10Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +56.5%
$566.4M to $886.5MCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Deteriorated: −6.4 pts
6.5% to 0.2%Significant
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Deteriorated: −3.0 pts
-0.1% to -3.2%Significant
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: +9.3%
$1.33B to $1.46BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +1.5 pts
37.3% to 38.9%Notable
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Improved: -9.2%
$12.79B to $11.61BNotable
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Q2 FY2026 against Q1 FY2026, from the 10-Q filed Aug 6, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Improved: turned positive
-$79.7M to $6.3MCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: turned negative
$176.4M to -$118.8MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Deteriorated: −8.2 pts
5.0% to -3.2%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: turned negative
$0.15 to -$0.10Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Deteriorated: -50.9%
$1.80B to $886.5MCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +25.9%
$1.16B to $1.46BSignificant
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +5.9 pts
33.0% to 38.9%Significant
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Improved: +6.7%
$3.51B to $3.75BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +2.4 pts
-2.3% to 0.2%Notable
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: -6.5%
$12.41B to $11.61BNotable
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
3 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 2% and 6%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Opinions from 18 analysts covering this company, as of . Their views, not this site's.
Of 18 analysts publishing on this company, 6 say strong buy, 6 say buy, 5 say hold and 1 say sell. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 3.5% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
Trailing P/E is not meaningful because the latest trailing earnings are zero or negative. The price-to-book and price-to-sales figures below still provide reference points.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
| -24.7% |
| — |
| 1.53x |
| MRKMerck & Co., Inc. | 9.0/10 | 5/9 | 1.3% | 28.1% | 20.38x | 1.60x |
|---|
| PFEPFIZER INC | 7.0/10 | 6/9 | -1.6% | 12.4% | 22.19x | 1.40x |
|---|
| BMYBRISTOL MYERS SQUIBB CO | 8.0/10 | 9/9 | -0.2% | 14.6% | 18.12x | 3.87x |
|---|
| ZTSZoetis Inc. | 9.0/10 | 7/9 | 2.3% | 28.2% | 13.04x | 3.64x |
|---|
| Median of peers | 8.5/10 | — | 0.5% | 21.4% | 19.25x | 2.62x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Exercised stock options — 999 shares
Holds 234,879 shares after this filing.
Had shares withheld to cover taxes — 435 shares at $16.23 ($7.1K)
Holds 234,444 shares after this filing.
Sold on the open market — 50,076 shares at $16.17 ($809.8K)
Holds 316,212 shares after this filing.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Published results · Reported another event
Signed a material agreement · Took on a direct financial obligation
Read the filingSigned a material agreement · Took on a direct financial obligation
Read the filingReported another event
Read the filingHeld a shareholder vote
Read the filingQuarterly report for Q1 FY2026
Revenue +8.2% · Operating margin +86.6 pts · Operating income $2.80B narrower — against Q1 FY2025
Read the filingPublished results · Reported another event
Read the filingHad a director or senior officer leave or join · Made a Regulation FD disclosure
Read the filingProxy statement for a shareholder meeting
Read the filingAnnual report for FY2025
Operating margin −18.8 pts · Operating income turned negative · Profit $2.88B wider — against FY2024
Read the filingAnnounced restructuring or exit costs · Published results · Reported another event
Read the filingHad a director or senior officer leave or join
Read the filingMade a Regulation FD disclosure
Read the filingHeld a shareholder vote
Read the filingHad a director or senior officer leave or join
Read the filingQuarterly report for Q3 FY2025
Operating margin −1.3 pts · Profit turned negative · Earnings per share turned negative — against Q3 FY2024
Read the filingPublished results · Reported another event
Read the filingAmended its charter or changed its financial year · Received shareholder director nominations · Reported another event
Read the filingThe first 40 of 276. The rest are in the exhibit.
Source: Exhibit 21 of the 10-K filed 2026-02-26. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Coverage from the last 30 days
A Look Back at Generic Pharmaceuticals Stocks’ Q2 Earnings: Viatris (NASDAQ:VTRS) Vs The Rest Of The Pack
Yahoo ·
JP Morgan Maintains Neutral on Viatris, Raises Price Target to $20
Benzinga ·
S&P 500 After-Hours Movers: Oct. 20 Gainers and Decliners
ChartMill ·
Viatris’ Dividend Has Room to Grow, but Will Management Deliver?
Yahoo ·
Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia
Yahoo ·
Opus Genetics Secures FDA Approval For Eye Drops – Set To Receive Milestone Payment
Yahoo ·
Viatris Receives FDA Approval For RYZUMVI To Treat Presbyopia In Adults
Benzinga ·
Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
Yahoo ·
Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade)
SeekingAlpha ·
Exploring the top movers within the S&P500 index during today's session.
ChartMill ·
Viatris: Is The Pacira Deal A Game Changer? (Rating Upgrade)
SeekingAlpha ·
Stocktwits M&A Watch: Viatris-Pacira Deal, Coca-Cola’s Costa Coffee Sale, Devon’s Eagle Ford Divestiture In Focus
Yahoo ·
Primary sources and further research